Patient characteristics at baseline
| Patients treated at M0 | Patients treated at M3 | Patients not treated at M3 | |
| n=730 | n=574 | n=156 | |
| Age at baseline (years) | |||
| Mean±SD | 55.0±13.1 | 55.2±13.1 | 54.4±13.0 |
| Gender (women; n (%)) | 569 (77.9%) | 442 (77.0%) | 127 (81.4%) |
| Body mass index (kg/m²) | |||
| Women; mean±SD | 25.25±5.37 (n=558) | 25.23±5.40 (n=435) | 25.31±5.29 (n=123) |
| Men; mean±SD | 25.52±3.99 (n=156) | 25.62±3.84 (n=128) | 25.04±4.68 (n=28) |
| Disease duration (years) | (n=728) | (n=572) | (n=156) |
| Mean±SD | 8.79±8.79 | 8.63±8.86 | 9.41±8.50 |
| Tender/painful joint count (28 joints) | (n=721) | (n=568) | (n=153) |
| Mean±SD | 8.93±7.04 | 8.71±6.96 | 9.74±7.27 |
| Swollen joint count (28 joints) | (n=719) | (n=567) | (n=152) |
| Mean±SD | 5.64±5.05 | 5.60±4.99 | 5.77±5.30 |
| CDAI score | (n=698) | (n=549) | (n=149) |
| Mean±SD | 25.72±12.35 | 25.17±12.29 | 27.73±12.39 |
| DAS28(ESR) score | (n=643) | (n=509) | (n=134) |
| Mean±SD | 4.84±1.27 | 4.79±1.27 | 5.05±1.27 |
| Low (DAS28≤3.2) | 62 (9.6%) | 52 (10.2%) | 10 (7.5) |
| Moderate (3.2≤DAS28≤5.1) | 318 (49.5%) | 256 (50.3%) | 62 (46.3) |
| High (DAS28>5.1) | 263 (40.9%) | 201 (39.5%) | 62 (46.3) |
| HAQ-DI total score | (n=692) | (n=545) | (n=147) |
| Mean±SD | 1.27±0.69 | 1.23±0.69 | 1.42±0.69 |
| Rheumatoid factor | (n=378) | (n=314) | (n=64) |
| Positive, n (%) | 263 (69.6%) | 218 (69.4%) | 45 (70.3%) |
| Anti-CCP antibodies | (n=396) | (n=324) | (n=72) |
| Positive, n (%) | 292 (73.7%) | 237 (73.1%) | 55 (76.4%) |
| Antirheumatic drug treatments prior to CZP initiation | (n=730) | (n=574) | (n=156) |
| No DMARDs | 8 (1.1%) | 7 (1.2%) | 1 (0.6%) |
| Conventional synthetic DMARDs | 712 (97.5%) | 560 (97.6%) | 152 (97.4%) |
| Methotrexate | 682 (93.4%) | 540 (94.1%) | 142 (91.0%) |
| Biological DMARDs | 240 (32.9%) | 175 (30.5%) | 65 (41.7%) |
| Anti-TNF agents | 221 (30.3%) | 163 (28.4%) | 58 (37.2%) |
| NSAIDS | 403 (55.2%) | 314 (54.7) | 89 (57.1) |
| Glucocorticoids | 562 (77.0%) | 444 (77.4) | 118 (75.6) |
| Antirheumatic drug treatments concomitant to CZP initiation | (n=730) | (n=574) | (n=156) |
| No DMARDs | 259 (35.5%) | 203 (35.4%) | 56 (35.9%) |
| Conventional synthetic DMARDs | 471 (64.5%) | 371 (64.6%) | 100 (64.1%) |
| Methotrexate | 391 (53.6%) | 315 (54.9%) | 76 (48.7%) |
| Leflunomide | 63 (8.6%) | 43 (7.5%) | 20 (12.8%) |
| Hydroxychloroquine | 21 (2.9%) | 16 (2.8%) | 5 (3.2%) |
| Sulfasalazine | 17 (2.3%) | 14 (2.4%) | 3 (1.9%) |
| NSAIDS | 258 (35.3%) | 198 (34.5) | 60 (38.5) |
| Glucocorticoids | 373 (51.1%) | 288 (50.2) | 85 (54.5) |
CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Score; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; NSAID, non-steroidal anti-inflammatory drug; TNF, tumour necrosis factor.